A multicentre, multinational, double blind, randomised, parallel group, placebo-controlled study of ethyl-eicosapentaenoate (EPA) in patients with Huntington's disease (HD)

Update Il y a 4 ans
Reference: ISRCTN79170611

Extract

Not provided at time of registration


Inclusion criteria

  • Huntington's disease

Links